By assessing the distribution of Aβ or phosphorylated tau in different brain regions from preclinical stage or moderate cognitive impairment to dementia of AD, PET imaging [51] can offer the metabolic changes in AD brain. This evidence concerns the gene MAPT and Cognitive impairment.